On this episode, Dennis Walker talks with Aaron Paul Orsini, the co-founder of Autistic Psychedelic Community, author of Autism on Acid, and producer of the recently released, therapy-friendly instrumental music album “Psychedelic Symphonies."
Similar Posts
MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)
MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!
In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.
As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.
Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?
Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.
Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.
This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.
Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/
MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2
Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #DMT #MNMD
Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022 | Science, Funding, Stocks & More
The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health?
Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year.
The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the Horizons Psychedelics ETF (PSYK) and the Advisor Shares Psychedelics ETF (PSIL), and 2021 was a huge year for the advent of public companies in the psychedelic medicines space.
The next big story was uplistings. Not all stock markets are created equal. In order to have the prestigious needed to attract serious money, companies need to be on exchanges such as the Nasdaq, NYSE, and the TSX. In 2021 we saw MindMed, Numinus, Field Trip, Cybin, and more join the big boys league.
Third, was funding. Psychedelic companies are for the most part biotech companies. In order to get a new drug through the clinical trial process, it takes hundreds of millions of dollars. This year we saw atai, Compass, MindMed, Cybin, and Field Trip, among others, raise over a billion dollars for the industry. This will sustain them for years to come.
And finally, 2021 saw a few high-profile clinical trials. The most significant was the MAPS Phase 3 clinical trial, which treated PTSD with MDMA-assisted therapy. The results of this trial were earth-shattering. Equally important was the Compass phase 2b trial, treating treatment-resistant depression with Psilocybin.
Moving into the new year, I am excited to see more clinical trials, and I expect to see mergers in the field.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Psychedelics #MindMed #Psylocybin
MindMed (MMED) Cluster Headaches LSD Trials Update (and response to criticisms)
Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!
P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”
Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.
Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.
Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?
🎵 Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf
Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!
Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain
Enjoy!
Links:
Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793
Increased depression in North America:
https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
Opioid Overdose In Ontario:
https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080
FDA Greenlights Ketamine:
https://psychedelicspotlight.com/ketamine-study-parkinsons-disease-treatment/
California Bill to Decriminalize Psychedelics Passes Senate Floor:
https://www.marijuanamoment.net/california-bill-to-legalize-possession-of-psychedelics-heads-to-senate-floor-after-committee-action/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #PsychedelicIndustry
BREAKING NEWS: Psychedelics ETF, PSIL, to launch THIS WEEK
BREAKING NEWS: Advisor Share Psychedelic Medicines ETF, PSIL, is going live THIS WEEK!!!!
Investing in ETFs can be a good way for retail investors to cash in on the shroom boom. This actively managed ETF will be managed by professionals who will do research on which companies have scientific and financial advantages.
PSIL will be on the NYSE, and will most likely feature companies such as MindMed (MNMD), Compass Pathways (CMPS), atai Life Sciences (atai), Numinus (NUMI) and more.
It will be a pure play psychedelics medicines ETF, and will not include marijuana companies (YAY). This means companies working with LSD, MDMA, Psilocybin and more. Primarily it is focused on improving mental health, so tackling problems like depression, PTSD addiction and more
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#AdvisorShares #PSIL #ThePsychedelicInvestor